Kos Announces Appointment of Vice President of Marketing

Apr 25, 2001, 01:00 ET from Kos Pharmaceuticals, Inc.

    MIAMI, April 25 /PRNewswire/ -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP)
 announced today the appointment of John P. Hampilos as Vice President of
 Marketing.  Mr. Hampilos will be responsible for the marketing, promotion, and
 physician education efforts for all of the company's products, including the
 company's new extended-release niacin/lovastatin combination product,
 Advicor(TM), currently under review by the U.S. Food and Drug Administration
 (FDA) for the treatment of dyslipidemia, or multiple lipid disorders.  The
 Advicor(TM) combination product could be cleared for marketing by the FDA in
 the second half of the year.  Upon approval, Advicor(TM) will be jointly
 launched and marketed by Kos and its co-promotion partner, DuPont
 Pharmaceuticals Company.
     Mr. Hampilos, 41, joins Kos following a 13-year career at Bristol-Myers
 Squibb Company in a variety of sales and marketing management positions, in
 which he had specific experience in launching products in the cholesterol
 area.  He received a Bachelors degree from the University of Illinois and
 Ph.D. and Masters degrees in Behavioral Science from Columbia University.  He
 is a resident of Ridgewood, New Jersey, and will work out of the company's
 office in Edison, New Jersey.
     Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical
 company engaged in developing and commercializing proprietary prescription
 pharmaceutical products, primarily for the treatment of chronic cardiovascular
 and respiratory diseases.  The Company currently markets its internally-
 developed Niaspan(R) product, its proprietary once-daily niacin formulation
 for the treatment of cholesterol disorders, and two anti-hypertensive
 products, Mavik(R) and Tarka(R), under a co-marketing arrangement with Abbott
 Laboratories, Inc.  Kos has drug delivery capabilities in both solid-dose and
 aerosolized formulation technologies.
     Certain statements in this press release, including statements relating to
 the timing of the FDA's expected clearance of Advicor(TM) and the expected
 launch of Advicor(TM), are forward-looking and are subject to risks and
 uncertainties.  These risks and uncertainties include the Company's ability to
 meet the conditions necessary to obtain funding under its funding
 arrangements, including payments from DuPont, the timing for the development
 and approval of Advicor(TM), the ability of both Kos and DuPont to build
 awareness for Advicor(TM) within the medical community, the continuation of
 Kos' partnership arrangements with DuPont, the effect of conditions in the
 pharmaceutical industry and the economy in general, as well as certain other
 risks.  A more detailed discussion of risks attendant to the forward-looking
 statements included in this press release is set forth in the "Forward-Looking
 Information: Certain Cautionary Statements" section of the Company's Annual
 Report on Form 10-K for the period ended December 31, 2000, filed with the
 Securities and Exchange Commission, and in other reports filed with the SEC.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75835402
 
 

SOURCE Kos Pharmaceuticals, Inc.
    MIAMI, April 25 /PRNewswire/ -- Kos Pharmaceuticals, Inc. (Nasdaq: KOSP)
 announced today the appointment of John P. Hampilos as Vice President of
 Marketing.  Mr. Hampilos will be responsible for the marketing, promotion, and
 physician education efforts for all of the company's products, including the
 company's new extended-release niacin/lovastatin combination product,
 Advicor(TM), currently under review by the U.S. Food and Drug Administration
 (FDA) for the treatment of dyslipidemia, or multiple lipid disorders.  The
 Advicor(TM) combination product could be cleared for marketing by the FDA in
 the second half of the year.  Upon approval, Advicor(TM) will be jointly
 launched and marketed by Kos and its co-promotion partner, DuPont
 Pharmaceuticals Company.
     Mr. Hampilos, 41, joins Kos following a 13-year career at Bristol-Myers
 Squibb Company in a variety of sales and marketing management positions, in
 which he had specific experience in launching products in the cholesterol
 area.  He received a Bachelors degree from the University of Illinois and
 Ph.D. and Masters degrees in Behavioral Science from Columbia University.  He
 is a resident of Ridgewood, New Jersey, and will work out of the company's
 office in Edison, New Jersey.
     Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical
 company engaged in developing and commercializing proprietary prescription
 pharmaceutical products, primarily for the treatment of chronic cardiovascular
 and respiratory diseases.  The Company currently markets its internally-
 developed Niaspan(R) product, its proprietary once-daily niacin formulation
 for the treatment of cholesterol disorders, and two anti-hypertensive
 products, Mavik(R) and Tarka(R), under a co-marketing arrangement with Abbott
 Laboratories, Inc.  Kos has drug delivery capabilities in both solid-dose and
 aerosolized formulation technologies.
     Certain statements in this press release, including statements relating to
 the timing of the FDA's expected clearance of Advicor(TM) and the expected
 launch of Advicor(TM), are forward-looking and are subject to risks and
 uncertainties.  These risks and uncertainties include the Company's ability to
 meet the conditions necessary to obtain funding under its funding
 arrangements, including payments from DuPont, the timing for the development
 and approval of Advicor(TM), the ability of both Kos and DuPont to build
 awareness for Advicor(TM) within the medical community, the continuation of
 Kos' partnership arrangements with DuPont, the effect of conditions in the
 pharmaceutical industry and the economy in general, as well as certain other
 risks.  A more detailed discussion of risks attendant to the forward-looking
 statements included in this press release is set forth in the "Forward-Looking
 Information: Certain Cautionary Statements" section of the Company's Annual
 Report on Form 10-K for the period ended December 31, 2000, filed with the
 Securities and Exchange Commission, and in other reports filed with the SEC.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X75835402
 
 SOURCE  Kos Pharmaceuticals, Inc.